New hope for Tough-to-Treat lymphoma: experimental transplant approach
NCT ID NCT07225985
Summary
This study is testing a new treatment approach for adults whose T-cell lymphoma has returned or hasn't responded to previous therapies. It combines two chemotherapy drugs (pralatrexate and bendamustine) with low-dose total body radiation, followed by a stem cell transplant from a donor. The main goals are to find the safest dose of pralatrexate and see if this combination helps more patients successfully receive a transplant compared to past treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.